Genetics and genomics of pulmonary arterial hypertension.

[1]  S. Erzurum,et al.  Altered MicroRNA processing in heritable pulmonary arterial hypertension: an important role for Smad-8. , 2011, American journal of respiratory and critical care medicine.

[2]  Howard Y. Chang,et al.  Disruption of PPARγ/β-catenin-mediated regulation of apelin impairs BMP-induced mouse and human pulmonary arterial EC survival. , 2011, The Journal of clinical investigation.

[3]  P. Mistry,et al.  Pulmonary vascular disease in Gaucher disease: clinical spectrum, determinants of phenotype and long-term outcomes of therapy , 2011, Journal of Inherited Metabolic Disease.

[4]  E. Paquet,et al.  The Journal of Experimental Medicine CORRESPONDENCE , 2005 .

[5]  E. Olson,et al.  Pervasive roles of microRNAs in cardiovascular biology , 2011, Nature.

[6]  M. Varella‐Garcia,et al.  Somatic chromosome abnormalities in the lungs of patients with pulmonary arterial hypertension. , 2010, American journal of respiratory and critical care medicine.

[7]  M. Geraci,et al.  Altered Immune Phenotype in Peripheral Blood Cells of Patients with Scleroderma‐Associated Pulmonary Hypertension , 2010, Clinical and translational science.

[8]  G. Stellin,et al.  Scimitar Syndrome: A European Congenital Heart Surgeons Association (ECHSA) Multicentric Study , 2010, Circulation.

[9]  W. Seeger,et al.  Dysregulation of the IL-13 receptor system: a novel pathomechanism in pulmonary arterial hypertension. , 2010, American journal of respiratory and critical care medicine.

[10]  B. Bruneau.  Epigenetic regulation of the cardiovascular system: introduction to a review series. , 2010, Circulation research.

[11]  E. K. Weir,et al.  Basic Science of Pulmonary Arterial Hypertension for Clinicians: New Concepts and Experimental Therapies , 2010, Circulation.

[12]  C. Panagiotopoulos,et al.  Primary Pulmonary Arterial Hypertension and Autoimmune Polyendocrine Syndrome in a Pediatric Patient , 2010, Pediatric Cardiology.

[13]  D. Tregouet,et al.  Clinical outcomes of pulmonary arterial hypertension in patients carrying an ACVRL1 (ALK1) mutation. , 2010, American journal of respiratory and critical care medicine.

[14]  Ferhaan Ahmad,et al.  Genomewide RNA expression profiling in lung identifies distinct signatures in idiopathic pulmonary arterial hypertension and secondary pulmonary hypertension. , 2010, American journal of physiology. Heart and circulatory physiology.

[15]  B. Krishnamachary,et al.  Hypoxia inducible-factor1alpha regulates the metabolic shift of pulmonary hypertensive endothelial cells. , 2010, The American journal of pathology.

[16]  J. Catravas,et al.  Effect of PPARgamma inhibition on pulmonary endothelial cell gene expression: gene profiling in pulmonary hypertension. , 2009, Physiological genomics.

[17]  C. Vizza,et al.  Acute Hemodynamic Effects of Single‐Dose Sildenafil When Added to Established Bosentan Therapy in Patients With Pulmonary Arterial Hypertension: Results of the COMPASS‐1 Study , 2009, Journal of clinical pharmacology.

[18]  P. Jones,et al.  Defective pulmonary vascular remodeling in Smad8 mutant mice. , 2009, Human molecular genetics.

[19]  E. Jackson,et al.  2-methoxyestradiol attenuates bleomycin-induced pulmonary hypertension and fibrosis in estrogen-deficient rats. , 2009, Vascular pharmacology.

[20]  R. Speich,et al.  Interleukin-6 Modulates the Expression of the Bone Morphogenic Protein Receptor Type II Through a Novel STAT3–microRNA Cluster 17/92 Pathway , 2009, Circulation research.

[21]  F. Parl,et al.  Alterations in oestrogen metabolism: implications for higher penetrance of familial pulmonary arterial hypertension in females , 2009, European Respiratory Journal.

[22]  R. Matsuoka,et al.  A new nonsense mutation of SMAD8 associated with pulmonary arterial hypertension , 2009, Journal of Medical Genetics.

[23]  N. Morrell,et al.  Altered Bone Morphogenetic Protein and Transforming Growth Factor-β Signaling in Rat Models of Pulmonary Hypertension: Potential for Activin Receptor-Like Kinase-5 Inhibition in Prevention and Progression of Disease , 2009, Circulation.

[24]  S. Heath,et al.  Investigation of the fine structure of European populations with applications to disease association studies , 2008, European Journal of Human Genetics.

[25]  J. Cogan,et al.  Gene expression in BMPR2 mutation carriers with and without evidence of Pulmonary Arterial Hypertension suggests pathways relevant to disease penetrance , 2008, BMC Medical Genomics.

[26]  N. Voelkel,et al.  The cancer paradigm of severe pulmonary arterial hypertension. , 2008, American journal of respiratory and critical care medicine.

[27]  M. Humbert,et al.  Severe pulmonary arterial hypertension: a forme fruste of cancer? , 2008, American journal of respiratory and critical care medicine.

[28]  Robert C. Saunders,et al.  What Patients and Their Relatives Think About Testing for BMPR2 , 2008, Journal of Genetic Counseling.

[29]  M. Humbert,et al.  Pulmonary Veno-Occlusive Disease: Clinical, Functional, Radiologic, and Hemodynamic Characteristics and Outcome of 24 Cases Confirmed by Histology , 2008, Medicine.

[30]  M. Humbert,et al.  Clinical outcomes of pulmonary arterial hypertension in carriers of BMPR2 mutation. , 2008, American journal of respiratory and critical care medicine.

[31]  J. Knowles,et al.  Clinical implications of determining BMPR2 mutation status in a large cohort of children and adults with pulmonary arterial hypertension. , 2008, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[32]  N. Rudarakanchana,et al.  Stoichiometric imbalance in the receptor complex contributes to dysfunctional BMPR-II mediated signalling in pulmonary arterial hypertension. , 2008, Human molecular genetics.

[33]  H. Dietz,et al.  Synergistic heterozygosity for TGFβ1 SNPs and BMPR2 mutations modulates the age at diagnosis and penetrance of familial pulmonary arterial hypertension , 2008, Genetics in Medicine.

[34]  E. Jackson,et al.  2-Ethoxyestradiol is antimitogenic and attenuates monocrotaline-induced pulmonary hypertension and vascular remodeling. , 2008, Vascular pharmacology.

[35]  N. Muntjewerff,et al.  ESHRE PGD Consortium data collection V: cycles from January to December 2002 with pregnancy follow-up to October 2003. , 2008, Human reproduction.

[36]  Fen Li,et al.  A novel mutation in the BMPR2 gene in familial pulmonary arterial hypertension. , 2008, Chinese medical journal.

[37]  J. Newman,et al.  Narrative Review: The Enigma of Pulmonary Arterial Hypertension: New Insights from Genetic Studies , 2008, Annals of Internal Medicine.

[38]  V. Kurup,et al.  Pulmonary arterial remodeling induced by a Th2 immune response , 2008, The Journal of experimental medicine.

[39]  M. Humbert,et al.  Pulmonary arterial hypertension associated with fenfluramine exposure: report of 109 cases , 2008, European Respiratory Journal.

[40]  M. Maitland,et al.  Mitochondrial metabolism, redox signaling, and fusion: a mitochondria-ROS-HIF-1alpha-Kv1.5 O2-sensing pathway at the intersection of pulmonary hypertension and cancer. , 2008, American journal of physiology. Heart and circulatory physiology.

[41]  W. Chung,et al.  Pulmonary artery hypertension in a child with MELAS due to a point mutation of the mitochondrial tRNA(Leu) gene (m.3243A>G) , 2008, Journal of Inherited Metabolic Disease.

[42]  H. Popper,et al.  Early-life pulmonary arterial hypertension with subsequent development of diffuse pulmonary arteriovenous malformations in hereditary haemorrhagic telangiectasia type 1 , 2007, Thorax.

[43]  R. Trembath,et al.  Characterization of the BMPR2 5'-untranslated region and a novel mutation in pulmonary hypertension. , 2007, American journal of respiratory and critical care medicine.

[44]  S. Erzurum,et al.  Hyperproliferative apoptosis-resistant endothelial cells in idiopathic pulmonary arterial hypertension. , 2007, American journal of physiology. Lung cellular and molecular physiology.

[45]  R. Pyeritz,et al.  Is pulmonary arterial hypertension in neurofibromatosis type 1 secondary to a plexogenic arteriopathy? , 2007, Chest.

[46]  A. Barabasi,et al.  Human disease classification in the postgenomic era: A complex systems approach to human pathobiology , 2007, Molecular systems biology.

[47]  W. Seeger,et al.  Receptor for Activated C-Kinase 1, a Novel Interaction Partner of Type II Bone Morphogenetic Protein Receptor, Regulates Smooth Muscle Cell Proliferation in Pulmonary Arterial Hypertension , 2007, Circulation.

[48]  Brinda K Rana,et al.  Function of Kv1.5 channels and genetic variations of KCNA5 in patients with idiopathic pulmonary arterial hypertension. , 2007, American journal of physiology. Cell physiology.

[49]  R. Baughman,et al.  Pulmonary hypertension in neurofibromatosis. , 2007, The American journal of cardiology.

[50]  Raed A Dweik,et al.  Alterations of cellular bioenergetics in pulmonary artery endothelial cells , 2007, Proceedings of the National Academy of Sciences.

[51]  C. Junien,et al.  Association between an endoglin gene polymorphism and systemic sclerosis-related pulmonary arterial hypertension. , 2006, Rheumatology.

[52]  M. Humbert,et al.  Genes and Pulmonary Arterial Hypertension , 2006, Respiration.

[53]  J. Cogan,et al.  High frequency of BMPR2 exonic deletions/duplications in familial pulmonary arterial hypertension. , 2006, American journal of respiratory and critical care medicine.

[54]  S. Archer,et al.  An Abnormal Mitochondrial–Hypoxia Inducible Factor-1&agr;–Kv Channel Pathway Disrupts Oxygen Sensing and Triggers Pulmonary Arterial Hypertension in Fawn Hooded Rats: Similarities to Human Pulmonary Arterial Hypertension , 2006, Circulation.

[55]  Eric W. Glissmeyer,et al.  Relationship of BMPR2 Mutations to Vasoreactivity in Pulmonary Arterial Hypertension , 2006, Circulation.

[56]  B. Gallie,et al.  Hereditary haemorrhagic telangiectasia: mutation detection, test sensitivity and novel mutations , 2006, Journal of Medical Genetics.

[57]  M. Humbert,et al.  Pulmonary arterial hypertension in France: results from a national registry. , 2006, American journal of respiratory and critical care medicine.

[58]  W. Seeger,et al.  Impact of TASK-1 in Human Pulmonary Artery Smooth Muscle Cells , 2006, Circulation research.

[59]  Eric W. Glissmeyer,et al.  Genetic association of the serotonin transporter in pulmonary arterial hypertension. , 2006, American journal of respiratory and critical care medicine.

[60]  M. Humbert,et al.  Serotonin transporter polymorphisms in familial and idiopathic pulmonary arterial hypertension. , 2006, American journal of respiratory and critical care medicine.

[61]  J. Carlquist,et al.  Mutations of the TGF‐β type II receptor BMPR2 in pulmonary arterial hypertension , 2006, Human mutation.

[62]  M. Humbert,et al.  BMPR2 gene rearrangements account for a significant proportion of mutations in familial and idiopathic pulmonary arterial hypertension , 2006, Human mutation.

[63]  G. Semenza.  Involvement of hypoxia-inducible factor 1 in pulmonary pathophysiology. , 2005, Chest.

[64]  B. Janssen,et al.  Serotonin transporter gene polymorphism in a cohort of German patients with idiopathic pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension. , 2005, Chest.

[65]  Michael R Pinsky,et al.  Cardiovascular issues in respiratory care. , 2005, Chest.

[66]  Mark I McCarthy,et al.  What makes a good genetic association study? , 2005, The Lancet.

[67]  J. Knowles,et al.  Bone morphogenetic protein receptor type II C-terminus interacts with c-Src: implication for a role in pulmonary arterial hypertension. , 2005, American journal of respiratory cell and molecular biology.

[68]  N. Voelkel,et al.  Initial apoptosis is followed by increased proliferation of apoptosis‐resistant endothelial cells , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[69]  Ning Chen,et al.  Novel mutations and polymorphisms in genes causing hereditary hemorrhagic telangiectasia , 2005, Human mutation.

[70]  J. Cogan,et al.  Gross BMPR2 gene rearrangements constitute a new cause for primary pulmonary hypertension , 2005, Genetics in Medicine.

[71]  R. Trembath,et al.  Investigation of Second Genetic Hits at the BMPR2 Locus as a Modulator of Disease Progression in Familial Pulmonary Arterial Hypertension , 2005, Circulation.

[72]  M. Daly,et al.  Genome-wide association studies for common diseases and complex traits , 2005, Nature Reviews Genetics.

[73]  R. Trembath,et al.  Transforming Growth Factor-&bgr; Receptor Mutations and Pulmonary Arterial Hypertension in Childhood , 2005 .

[74]  K. Bussell.  Signalling: Friendly rivalry , 2005, Nature Reviews Molecular Cell Biology.

[75]  R. Ewert,et al.  Low frequency of BMPR2 mutations in a German cohort of patients with sporadic idiopathic pulmonary arterial hypertension , 2004, Journal of Medical Genetics.

[76]  S. P. Nana-Sinkam,et al.  Gene microarray analysis of peripheral blood cells in pulmonary arterial hypertension. , 2004, American journal of respiratory and critical care medicine.

[77]  C. Bartram,et al.  Primary Pulmonary Hypertension in Children May Have a Different Genetic Background Than in Adults , 2004, Pediatric Research.

[78]  A. Sola,et al.  A case of Adams–Oliver syndrome with associated brain and pulmonary involvement: Further evidence of vascular pathology? , 2004, American journal of medical genetics. Part A.

[79]  D. Chitayat,et al.  Abnormal pericyte recruitment as a cause for pulmonary hypertension in Adams–Oliver syndrome , 2004, American journal of medical genetics. Part A.

[80]  J. Knowles,et al.  BMPR2 mutations in pulmonary arterial hypertension with congenital heart disease , 2004, European Respiratory Journal.

[81]  D. Mccrory,et al.  Medical Therapy For Pulmonary Arterial Hypertension: ACCP Evidence-Based Clinical Practice Guidelines , 2004 .

[82]  D. Mccrory,et al.  Screening, early detection, and diagnosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. , 2004, Chest.

[83]  J. Knowles,et al.  Genetic basis of pulmonary arterial hypertension: current understanding and future directions. , 2004, Journal of the American College of Cardiology.

[84]  T. Kuriyama,et al.  Polymorphism of the promoter region of prostacyclin synthase gene in chronic thromboembolic pulmonary hypertension , 2004, Respirology.

[85]  M. Humbert,et al.  Endoglin germline mutation in a patient with hereditary haemorrhagic telangiectasia and dexfenfluramine associated pulmonary arterial hypertension , 2004, Thorax.

[86]  Ivan V. Gregoretti,et al.  Molecular evolution of the histone deacetylase family: functional implications of phylogenetic analysis. , 2004, Journal of molecular biology.

[87]  Toshihiro Tanaka.  The International HapMap Project , 2003, Nature.

[88]  N. Rudarakanchana,et al.  Functional interaction between BMPR-II and Tctex-1, a light chain of Dynein, is isoform-specific and disrupted by mutations underlying primary pulmonary hypertension. , 2003, Human molecular genetics.

[89]  R. Trembath,et al.  Molecular and functional analysis identifies ALK-1 as the predominant cause of pulmonary hypertension related to hereditary haemorrhagic telangiectasia , 2003, Journal of medical genetics.

[90]  E. Stanley,et al.  Direct signaling by the BMP type II receptor via the cytoskeletal regulator LIMK1 , 2003, The Journal of cell biology.

[91]  J. Massagué,et al.  Mechanisms of TGF-β Signaling from Cell Membrane to the Nucleus , 2003, Cell.

[92]  M. Humbert,et al.  Prognostic factors for survival in human immunodeficiency virus-associated pulmonary arterial hypertension. , 2003, American journal of respiratory and critical care medicine.

[93]  M. Hoeper,et al.  Lack of association between angiotensin converting enzyme (ACE) genotype, serum ACE activity, and haemodynamics in patients with primary pulmonary hypertension , 2003, Heart.

[94]  J. Newman,et al.  Pulmonary veno-occlusive disease caused by an inherited mutation in bone morphogenetic protein receptor II. , 2003, American journal of respiratory and critical care medicine.

[95]  B. Groves,et al.  Angiotensin-converting enzyme DD genotype in patients with primary pulmonary hypertension: increased frequency and association with preserved haemodynamics , 2003, Journal of the renin-angiotensin-aldosterone system : JRAAS.

[96]  E. Lander,et al.  Meta-analysis of genetic association studies supports a contribution of common variants to susceptibility to common disease , 2003, Nature Genetics.

[97]  N. Morrell,et al.  Characterization of high-altitude pulmonary hypertension in the Kyrgyz: association with angiotensin-converting enzyme genotype. , 2002, American journal of respiratory and critical care medicine.

[98]  J. Reveille,et al.  Mutations of bone morphogenetic protein receptor type II are not found in patients with pulmonary hypertension and underlying connective tissue diseases. , 2002, Arthritis and rheumatism.

[99]  S. Hodge,et al.  BMPR2 germline mutations in pulmonary hypertension associated with fenfluramine derivatives , 2002, European Respiratory Journal.

[100]  K. Miyazono,et al.  Functional heterogeneity of bone morphogenetic protein receptor-II mutants found in patients with primary pulmonary hypertension. , 2002, Molecular biology of the cell.

[101]  N. Rudarakanchana,et al.  Functional analysis of bone morphogenetic protein type II receptor mutations underlying primary pulmonary hypertension. , 2002, Human molecular genetics.

[102]  R. Trembath,et al.  Primary Pulmonary Hypertension Is Associated With Reduced Pulmonary Vascular Expression of Type II Bone Morphogenetic Protein Receptor , 2002, Circulation.

[103]  L. Newman,et al.  Genetic and environmental risk factors in beryllium sensitization and chronic beryllium disease. , 2002, Chest.

[104]  W. Seeger,et al.  Primary pulmonary hypertension is predominantly a hereditary disease. , 2002, Chest.

[105]  W. Seeger,et al.  Linkage analysis in a large family with primary pulmonary hypertension: genetic heterogeneity and a second primary pulmonary hypertension locus on 2q31-32. , 2002, Chest.

[106]  M. Humbert,et al.  Serotonin transporter overexpression is responsible for pulmonary artery smooth muscle hyperplasia in primary pulmonary hypertension. , 2001, The Journal of clinical investigation.

[107]  G. Semenza,et al.  Expression of angiogenesis‐related molecules in plexiform lesions in severe pulmonary hypertension: evidence for a process of disordered angiogenesis , 2001, The Journal of pathology.

[108]  M. Humbert,et al.  Clinical and molecular genetic features of pulmonary hypertension in patients with hereditary hemorrhagic telangiectasia. , 2001, The New England journal of medicine.

[109]  John Arul Phillips,et al.  Mutation in the gene for bone morphogenetic protein receptor II as a cause of primary pulmonary hypertension in a large kindred. , 2001, The New England journal of medicine.

[110]  C. Peers,et al.  Combined Antisense and Pharmacological Approaches Implicate hTASK as an Airway O2 Sensing K+Channel* , 2001, The Journal of Biological Chemistry.

[111]  N. Voelkel,et al.  Microsatellite Instability of Endothelial Cell Growth and Apoptosis Genes Within Plexiform Lesions in Primary Pulmonary Hypertension , 2001, Circulation research.

[112]  M. Humbert,et al.  Sporadic primary pulmonary hypertension is associated with germline mutations of the gene encoding BMPR-II, a receptor member of the TGF-β family , 2000, Journal of medical genetics.

[113]  C. Fischer,et al.  Abnormal Pulmonary Artery Pressure Response in Asymptomatic Carriers of Primary Pulmonary Hypertension Gene , 2000, Circulation.

[114]  S. Hodge,et al.  Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-II gene. , 2000, American journal of human genetics.

[115]  R. Trembath,et al.  Heterozygous germline mutations in BMPR2, encoding a TGF-β receptor, cause familial primary pulmonary hypertension , 2000, Nature Genetics.

[116]  M. Lazdunski,et al.  Inhalational anesthetics activate two-pore-domain background K+ channels , 1999, Nature Neuroscience.

[117]  K. Irie,et al.  p38 Mitogen-Activated Protein Kinase Can Be Involved in Transforming Growth Factor β Superfamily Signal Transduction in Drosophila Wing Morphogenesis , 1999, Molecular and Cellular Biology.

[118]  K. Shroyer,et al.  Monoclonal endothelial cells in appetite suppressant-associated pulmonary hypertension. , 1998, American journal of respiratory and critical care medicine.

[119]  K. Shroyer,et al.  Monoclonal endothelial cell proliferation is present in primary but not secondary pulmonary hypertension. , 1998, The Journal of clinical investigation.

[120]  A. Gurney,et al.  Regulation of the resting potential of rabbit pulmonary artery myocytes by a low threshold, O2‐sensing potassium current * , 1997, British journal of pharmacology.

[121]  J. Massagué,et al.  Human type II receptor for bone morphogenic proteins (BMPs): extension of the two-kinase receptor model to the BMPs , 1995, Molecular and cellular biology.

[122]  T. Foroud,et al.  Genetic anticipation and abnormal gender ratio at birth in familial primary pulmonary hypertension. , 1995, American journal of respiratory and critical care medicine.

[123]  T. Hunter,et al.  The eukaryotic protein kinase superfamily: kinase (catalytic) domain structure and classification 1 , 1995, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[124]  M. Kobayashi,et al.  Establishment of human endothelial cell lines in a serum-free culture and its application for expression of transfected prepro endothelin gene. , 1991, Human cell.

[125]  E H Bergofsky,et al.  Survival in Patients with Primary Pulmonary Hypertension: Results from a National Prospective Registry , 1991 .

[126]  N. Uren,et al.  Severe pulmonary hypertension in Ullrich-Noonan syndrome. , 1989, British heart journal.

[127]  D. Buff.  Primary pulmonary hypertension. , 1987, Annals of internal medicine.

[128]  E H Bergofsky,et al.  Primary pulmonary hypertension. A national prospective study. , 1987, Annals of internal medicine.

[129]  T. Rowland,et al.  Chronic upper airway obstruction and pulmonary hypertension in Down's syndrome. , 1981, American journal of diseases of children.

[130]  A. Nadas,et al.  The clinical course of cardiac disease in Down's syndrome. , 1976, Pediatrics.

[131]  D. Dresdale,et al.  Recent studies in primary pulmonary hypertension, including pharmacodynamic observations on pulmonary vascular resistance. , 1954, Bulletin of the New York Academy of Medicine.

[132]  W. Chung,et al.  Two Cases of Pulmonary Hypertension Associated with Type III Glycogen Storage Disease. , 2011, JIMD reports.

[133]  M. Furutani,et al.  Implications of mutations of activin receptor-like kinase 1 gene (ALK1) in addition to bone morphogenetic protein receptor II gene (BMPR2) in children with pulmonary arterial hypertension. , 2008, Circulation journal : official journal of the Japanese Circulation Society.

[134]  V. Leiro,et al.  [Mutations in the gene encoding bone morphogenetic protein receptor 2 in patients with idiopathic pulmonary arterial hypertension]. , 2008, Archivos de bronconeumologia.

[135]  Deni Elliott,et al.  Genetic Information Nondiscrimination Act , 2008 .

[136]  A. Baloira,et al.  Mutaciones en el gen que codifica BMPR2 en pacientes con hipertensión arterial pulmonar esporádica , 2008 .

[137]  Nathaniel Rothman,et al.  Assessing the probability that a positive report is false: an approach for molecular epidemiology studies. , 2004, Journal of the National Cancer Institute.

[138]  M. Humbert,et al.  BMPR2 haploinsufficiency as the inherited molecular mechanism for primary pulmonary hypertension. , 2001, American journal of human genetics.

[139]  S. Choe,et al.  Three-finger toxin fold for the extracellular ligand-binding domain of the type II activin receptor serine kinase. , 1999, Nature Structural Biology.

[140]  Hossein Baharvand,et al.  Genetics and genomics , 1998, Nature.